Evaluation of the effects of lofexidine and clonidine on naloxone-precipitated withdrawal in opioid-dependent humans

Addiction

Volumn 98, Issue 4, 2003, Pages 427-439

  Walsh, Sharon L ^a,b   Strain, Eric C ^a   Bigelow, George E ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Dept of Psychiat/Behav Sciences ^*  (United States)

Author keywords

Clonidine; Lofexidine; Naloxone; Opiate; Opioid withdrawal

Indexed keywords

ALPHA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BRITLOFEX; CLONIDINE; LOFEXIDINE; METHADONE; NALOXONE; OPIATE; PLACEBO; ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT; DRUG DERIVATIVE; NARCOTIC AGENT; NARCOTIC ANTAGONIST;

ADULT; ANAMNESIS; ARTICLE; AUTONOMIC DYSFUNCTION; BLOOD PRESSURE; CARDIOVASCULAR RESPONSE; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE CALCULATION; DOSE RESPONSE; DRUG DEPENDENCE; DRUG EFFECT; DRUG MECHANISM; FEMALE; GENDER; HEART RATE; HOSPITAL PATIENT; HUMAN; LABORATORY; LACRIMATION; MAINTENANCE THERAPY; MALE; MULTIPLE DRUG ABUSE; OPIATE ADDICTION; PROVOCATION TEST; PUPIL; RHINORRHEA; TIME; VOLUNTEER; WITHDRAWAL SYNDROME; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG COMBINATION; RANDOMIZED CONTROLLED TRIAL;

ADRENERGIC ALPHA-AGONISTS; ADULT; CLONIDINE; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; NALOXONE; NARCOTIC ANTAGONISTS; NARCOTICS; SUBSTANCE WITHDRAWAL SYNDROME;

EID: 0037392169     PISSN: 09652140     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1360-0443.2003.00372.x     Document Type: Article

References (42)

1. Aigner, A. & Schmidt, U. (1982) Lofexidine, a new, antihypertensive imidazoline derivative. Drug Research, 32, 976-983.
2. Anavekar, S. N., Jarrott, B., Toscano, M. & Louis, W. J. (1982) Pharmacokinetic and pharmacodynamic studies of oral clonidine in normotensive subjects. European Journal of Clinical Pharmacology, 23, 1-5.
3. Beam, J., Gossop, M. & Strang, J. (1996) Randomised double-blind comparison of lofexidine and methadone in the inpatient treatment of opiate withdrawal. Drug and Alcohol Dependence, 43, 87-91.
4. Bisaga, A., Comer, S., Ward, A., Popik, P., Kleber, H. & Fischman, M. (2001) The NMDA antagonist memantine attenuates the expression of opioid physical dependence in humans. Psychopharmacology, 157, 1-10.
5. Carnwath, T. & Hardman, J.-a. (1998) Randomised double-blind comparison of lofexidine and clonidine in the outpatient treatment of opiate withdrawal. Drug and Alcohol Dependence, 50, 251-254.
6. Charney, D., Riordan, C., Kleber, H., Murburg, M., Braverman, P., Sternberg, D., Henninger, G. & Redmond, D. (1982) Clonidine and naltrexone. A safe, effective and rapid treatment of abrupt withdrawal from methadone therapy. Archives of General Psychiatry, 39, 1327-1332.
7. Dollery, C. T. & Reid, J. L. (1982) Double-blind comparison of the hypotensive, sedative and salivary flow effects of lofexidine and clonidine in normal subjects. Drug Research, 32, 984-987.
8. Eissenberg, T., Greenwald, M. W., Johnson, R. E., Liebson, I. A., Bigelow, G. E. & Stitzer, M. L. (1996) Buprenorphine's physical dependence potential: antagonist-precipitated withdrawal in humans. Journal of Pharmacology and Experimental Therapeutics, 276, 449-459.
9. Fagan, T. C., Bloomfield, S. S., Cowart, T. D., Corns-Hurwitz, R. H., Lipicky, R. J., Conradi, E. C., Hsu, C.-Y., Grossman, W. J., Harmon, G. E., Degenhart, W. J., Sinkfield, A. W. & Gaffney, T. E. (1982) Antihypertensive effects of lofexidine in patients with essential hypertension. British Journal of Clinical Pharmacology, 13, 405-410.
10. First, M. B., Spitzer, R. L. & Gibbon, M. (1996) Structured Clinical Interview for DSM-IV Axis I Disorders. New York: New York State Psychiatric Institute.
11. Gerra, G., Marcato, A., Caccavari, R., Fontanesis, B., Delsignore, R., Fertonanai, G., Avanzini, P., Rustichelli, P. & Passeri, M. (1995) Clonidine and opiate receptor antagonists in the treatment of heroin addiction. Journal of Substance Abuse Treatment, 12, 35-41.
12. Gold, M., Pottash, A. L. C., Annito, W. J., Extein, I. & Kleber, H. D. (1981) Lofexidine, a clonidine analogue effective in opiate withdrawal. Lancet, I.
13. Gold, M., Redmond, D. & Kleber, H. (1978) Clonidine in opiate withdrawal. Lancet, 1, 929-930.
14. Goldberg, S. R. & Schuster, C. R. (1970) Conditioned nalorphine-induced abstinence changes: persistence in post morphine-dependent monkeys. Journal of Experimental Analysis and Behavior, 14, 33-46.
15. Gossop, M. (1988) Clonidine and the treatment of the opiate withdrawal syndrome. Drug and Alcohol Dependence, 21, 253-259.
16. Himmelsbach, C. K. (1941) The morphine abstinence syndrome, its nature and treatment. Annals of Internal Medicine, 15, 829-839.
17. 3H] clonidine binding in rat cerebral cortex. Biochemical Pharmacology, 27, 141-144.
18. Jasinski, D. R., Johnson, R. E. & Kocher, T. R. (1985) Clonidine in morphine withdrawal - differential effects on signs and symptoms. Archives of General Psychiatry, 42, 1063-1066.
19. Jasinski, D. R. Martin, W. R. & Haertzen, C. A. (1967) The human pharmacology and abuse potential of N-allylnoroxymorphone (naloxone). Journal of Pharmacology and Experimental Therapeutics, 157, 420-425.
20. Kahn, A., Mumford, J. P., Ash Rogers, G. & Beckford, H. (1997) Double-blind study of lofexidine and clonidine in the detoxification of opiate addicts in hospital. Drug and Alcohol Dependence, 44, 57-61.
21. Kleber, H. D., Riordan, C. E., Rounsaville, B. J., Kosten, T. R., Charney, D. S., Gaspari, J., Hogan, I. & O'Connor, C. (1985) Clonidine in outpatient detoxification from methadone maintenance. Archives of General Psychiatry, 42, 391-394.
22. Lamas, X., Farre, M. & Carol, J. (1994) Acute effects of pentazocine, naloxone and morphine in opioid-dependent volunteers. Journal of Pharmacology and Experimental Therapeutics, 268, 1485-1492.
23. Lopez, L. M. & Mehta, J. L. (1984) Comparative efficacy and safety of lofexidine and clonidine in mild to moderately severe systemic hypertension. American Journal of Cardiology, 53, 787-790.
24. 14C-lofexidine hydrochloride in man. Drug Research, 32, 972-975.
25. Myles, J. (1996) Alpha-2 andrenoceptors in addiction. Journal of Psychopharmacology, 10, 49-52.
26. O'Brien, C. P., O'Brien, T. J., Mintz, J. & Brady, J. P. (1975) Conditioning of narcotic abstinence symptoms in human subjects. Drug and Alcohol Dependence, 1, 115-123.
27. O'Brien, C. P., Testa, T., O'Brien, T. J., Brady, J. P. & Wells, B. (1977) Conditioned narcotic withdrawal of humans. Science, 195, 1000-1002.
28. Preston, K. L., Bigelow, G. E. & Liebson, I. A. (1985) Self-administration of clonidine, oxazepam, and hydromorphone by patients undergoing methadone detoxification. Clinical Pharmacology and Therapeutics, 38, 219-227.
29. Preston, K. L., Bigelow, G. E. & Liebson, I. A. (1988) Butorphanol-precipitated withdrawal in opioid-dependent human volunteers. Journal of Pharmacology and Experimental Therapeutics, 246, 441-448.
30. Reisine, T. & Pasternak, G. (1996) Opioid analgesics and antagonists. In: J. G. Hardman, L. E. Limbird, P. B. Molinoff, R. W. Ruddon & A. Goodman Gilman, eds. Goodman and Gilman's the Pharmacological Basis of Therapeutics, 9th edn, pp. 521-555. Chicago, IL: McGraw-Hill.
31. Rosen, M. L., McMahon, J., Hameedi, F. A., Pearsall, R., Woods, S. W., Kreek, M. J. & Kosten, T. R. (1996a) Effect of clonidine pretreatment on naloxone-precipitated opiate withdrawal. Journal of Pharmacology and Experimental Therapeutics, 276, 1128-1135.
32. Rosen, M. I. McMahon, T. J., Margolin, A., Gill, T. S., Woods, S. W., Pearsall, H. R., Kreek, M. J. & Kosten, T. R. (1995) Reliability of sequential naloxone challenge tests. American Journal of Drug and Alcohol Abuse, 21, 453-467.
33. Rosen, M., Pearsall, H., Woods, S. & Kosten, T. (1996b) The effect of gamma-hydroxybutyric acid on naloxone-precipitated opiate withdrawal. Neuropsychopharmacology, 14, 187-193.
34. Schuh, K. J., Walsh, S. L., Bigelow, G. E., Preston, K. L. & Stitzer, M. L. (1996) Buprenorphine, morphine and naloxone effects during ascending morphine maintenance in humans. Journal of Pharmacology and Experimental Therapeutics, 278, 836-846.
35. Schultz, H. S. S. D. C., Brewer, D. D., Eltorai, M. I. & Weber, M. A. (1981) Centrally acting antihypertensive agents: a comparison of lofexidine with clonidine. Journal of Clinical Pharmacology, 21, 65-71.
36. Shearman, G. T., Lal, H. & Ursillo, R. C. (1980) Effectiveness of lofexidine in blocking morphine-withdrawal signs in the rat. Pharmacology, Biochemistry and Behavior, 12, 573-575.
37. Strain, E. C., Preston, K. L., Liebson, I. A. & Bigelow, G. E. (1992) Acute effects of buprenorphine, hydromorphone and naloxone in methadone-maintained volunteers. Journal of Pharmacology and Experimental Therapeutics, 261, 985-993.
38. Walsh, S. L., Johnson, R. E., Cone, E. J. & Bigelow, G. E. (1998) Intravenous and oral 1-alpha-acetylmethadol: pharmacodynamics and pharmacokinetics in humans. Journal of Pharmacology and Experimental Therapeutics, 285, 71-82.
39. Washton, A. M. & Resnick, R. B. (1982) Lofexidine in abrupt methadone withdrawal. Psychopharmacology Bulletin, 18.
40. Wikler, A., Eraser, H. F. & Isbell, H. (1953) N-alylnormorphine: effects of single doses and precipitation of acute 'abstinence syndromes' during addiction to morphine, methadone and heroin in man (post-addicts). Journal of Pharmacology and Experimental Therapeutics, 109, 8-20.
41. Wikler, A. & Percor, F. T. (1967) Classical conditioning of a morphine abstinence phenomenon, reinforcement of opioid-drinking behavior and 'relapse' in morphine-addicted rats. Psychopharmacologia, 10, 255-284.
42. Wilkins, L. H., Winternitz, S. R., Oparil, S., Smith, L. R. & Dustan, H. P. (1981) Lofexidine and clonidine in moderate essential hypertension. Clinical Pharmacology and Therapeutics, 30, 752-757.